Progress in the development of baicalein and its clinical pharmacology study

doi:10.12092/j.issn.1009-2501.2020.06.013

Abstract

Abstract: The 2019 new coronavirus pneumonia (COVID-19) caused by the new coronavirus (SARS-Cov-2) infection has become a global pandemic, and currently there is a lack of specific antiviral drugs. Traditional Chinese medicine plays a critical role in the treatment of COVID-19. Scutellaria baicalensis is an important component of the Qingfei Paidu decoction recommended in the Chinese National Health Commission's Treatment Regimen and Wuhan Xiehe No.2 and No.3 prescriptions as well. Baicalein is the main ingredient in Scutellaria baicalensis, and has various pharmacological effects such as antiviral, antibacterial, antiallergic, and immunomodulatory activities, showing a broad prospect in new drug development. This article systemically reviewed the recent progress in the preclinical and clinical studies, potential drug interactions, and other aspects of baicalein, which will help further development and clinical application of the drug.

Key words: baicalein, antivirus, immunomodulation, clinical pharmacology

CLC Number:

R285

SHAN Hui, DU Yinxiao, BAI Hequn, CHEN Junxia, HE Xiaolin, WANG Qian, HU Zijian, LV Cheng, CHEN Xiaoping. Progress in the development of baicalein and its clinical pharmacology study[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 701-708.

References 48

[1]	Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [J]. Int J Antimicrob Agents, 2020, 55(3): 105924.
[2]	Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives [J]. Xenobiotica; the fate of foreign compounds in biological systems, 2010, 40(5): 357-367.
[3]	张海丽, 游雷鸣, 刘慧, 等. 汉黄芩素对LPS和ATP联合诱导的巨噬细胞炎症反应的抑制作用 [J]. 中国免疫学杂志, 2019, 35(9): 1059-1063.
[4]	张春辉, 邢雪琨, 张慧. 黄芩的药理作用研究 [J]. 中兽医医药杂志, 2020, 39(2): 98-100.
[5]	辛文妤, 宋俊科, 何国荣, 等. 黄芩素和黄芩苷的药理作用及机制研究进展 [J]. 中国新药杂志, 2013, 22(6): 647-653, 659.
[6]	王赫然, 王茜. 新型冠状病毒有关药物和生物制品研究进展 [J]. 药学学报, 2020, 55(3): 349-354.
[7]	Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J]. J Clin Virol, 2004, 31(1): 69-75.
[8]	Hour MJ, Huang SH, Chang CY, et al. Baicalein, ethyl acetate, and chloroform extracts of scutellaria baicalensis inhibit the neuraminidase activity of pandemic 2009 H1N1 and seasonal influenza a viruses [J]. Evid Based Complement Alternat Med, 2013, 2013: 750803.
[9]	Ahn HC, Lee SY, Kim JW, et al. Binding aspects of baicalein to HIV-1 integrase [J]. Mol Cells, 2001, 12(1): 127-130.
[10]	Michaelis M, Sithisarn P, Cinatl J Jr. Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A [J]. BMC Research Notes, 2014, 7: 384.
[11]	Johari J, Kianmehr A, Mustafa MR, et al. Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus [J]. Int J Mol Sci, 2012, 13(12): 16785-16795.
[12]	Oo A, Teoh BT, Sam SS, et al. Baicalein and baicalin as Zika virus inhibitors [J]. Arch Virol, 2019, 164(2): 585-593.
[13]	Liu Y, Yao W, Si L, et al. Chinese herbal extract Su-duxing had potent inhibitory effects on both wild-type and entecavir-resistant hepatitis B virus (HBV) in vitro and effectively suppressed HBV replication in mouse model [J]. Antiviral Res, 2018, 155: 39-47.
[14]	Keum YS. Inhibition of SARS coronavirus helicase by baicalein [J]. Soc, 2013, 34(11): 3187-3188.
[15]	Moghaddam E, Teoh BT, Sam SS, et al. Baicalin, a metabolite of baicalein with antiviral activity against dengue virus [J]. Sci Rep, 2014, 4: 5452.
[16]	吴莹, 金叶智, 吴珺, 等. 黄芩主要成分体外抗甲型流感病毒作用的研究 [J]. 北京中医药大学学报, 2010, 33(8): 541-545.
[17]	Zhi HJ, Zhu HY, Zhang YY, et al. In vivo effect of quantified flavonoids-enriched extract of Scutellaria baicalensis root on acute lung injury induced by influenza A virus [J]. Phytomedicine, 2019, 57: 105-116.
[18]	Xu G, Dou J, Zhang L, et al. Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum [J]. Biolog Pharmaceu Bull, 2010, 33(2): 238-243.
[19]	Chen L, Dou J, Su Z, et al. Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice [J]. Antiviral Res, 2011, 91(3): 314-320.
[20]	Pu WL, Bai RY, Zhou K, et al. Baicalein attenuates pancreatic inflammatory injury through regulating MAPK, STAT 3 and NF-κB activation [J]. Int Immunopharmacol, 2019, 72: 204-210.
[21]	Jang H, Lee J, Park S, et al. Baicalein mitigates radiation-induced enteritis by improving endothelial dysfunction [J]. Front Pharmacol, 2019, 10: 892.
[22]	王雷, 杨新建, 范玉强. 黄芩素滴丸对大鼠的急性毒性实验研究 [J]. 中国药房, 2013, 24(15): 1356-1359.
[23]	张喜平, 程琪辉, 陈君峰, 等. 黄芩素胶囊的小鼠急性毒性实验 [J]. 医学研究杂志, 2007, 36(4): 52-55.
[24]	沈安, 吴璐, 朱卫丰. 黄芩中黄芩苷与黄芩素的体内外转化研究进展[J]. 江西中医药, 2017, 48(9): 71-74.
[25]	Liu TM, Jiang XH. Investigation of the absorption mechanisms of baicalin and baicalein in rats [J]. J Pharm Sci, 2006, 95(6): 1326-1333.
[26]	Li W, Pi J, Zhang Y, et al. A strategy to improve the oral availability of baicalein: The baicalein-theophylline cocrystal [J]. Fitoterapia, 2018, 129: 85-93.
[27]	赵振宇, 董武军, 刘玉玲. 黄芩素在小鼠体内的药动学及其组织分布研究 [J]. 中国医药工业杂志, 2009, 40(9): 687-690.
[28]	Jia ZY, Bai ZZ, Jiang LJ, et al. Ocular pharmacokinetic study on baicalin in lens of rabbits following intragastric administration [J]. Graefes Arch Clin Exp Ophthalmol, 2010, 248(1): 59-63.
[29]	Tang Y, Zhu H, Zhang Y, et al. Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography [J]. Biomed Chromatogr, 2006, 20(10): 1116-1119.
[30]	Tian S, He G, Song J, et al. Pharmacokinetic study of baicalein after oral administration in monkeys [J]. Fitoterapia, 2012, 83(3): 532-540.
[31]	Xu P, Zhou H, Li YZ, et al. Baicalein enhances the oral bioavailability and hepatoprotective effects of silybin through the inhibition of efflux transporters BCRP and MRP2 [J]. Front Pharmacol, 2018, 9: 1115.
[32]	Xing J, Chen X, Zhong D. Absorption and enterohepatic circulation of baicalin in rats[J]. Life sciences, 2005, 78(2): 140-146.
[33]	Zhang L, Lin G, Zuo Z. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein [J]. Pharmaceu Res, 2007, 24(1): 81-89.
[34]	柳文媛, 徐维露, 李萍, 等. LC-MS/MS法研究黄芩素及其主要代谢物在大鼠体内的组织分布与排泄 [J]. 中国药科大学学报, 2009, 40(4): 348-352.
[35]	Li M, Shi A, Pang H, et al. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects [J]. J Ethnopharmacol, 2014, 156: 210-215.
[36]	Pang H, Xue W, Shi A, et al. Multiple-ascending-dose pharmacokinetics and safety evaluation of baicalein chewable tablets in healthy Chinese volunteers [J]. Clin Drug Invest, 2016, 36(9): 713-724.
[37]	Fan L, Wang JC, Jiang F, et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation [J]. Eur J Clin Pharmacol, 2009, 65(4): 403-409.
[38]	Fan L, Wang G, Wang LS, et al. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole [J]. Acta Pharmacol Sin, 2007, 28(10): 1685-1692.
[39]	Jang SI, Kim HJ, Hwang KM, et al. Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice [J]. Immunopharmacol Immunotoxicol, 2003, 25(4): 585-594.
[40]	Yue J, Peng R, Chen J, et al. Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats [J]. Pharmacol Res, 2009, 59(2): 112-119.
[41]	Tsai PL,Tsai TH. Pharmacokinetics of baicalin in rats and its interactions with cyclosporin A, quinidine and SKF-525A: a microdialysis study [J]. Planta Med, 2004, 70(11): 1069-1074.
[42]	Fan L, Zhang W, Guo D, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1 [J]. Clin Pharmacol Ther, 2008, 83(3): 471-476.
[43]	Itoh T, Itagaki S, Sumi Y, et al. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2 [J]. Cancer Chemother Pharmacol, 2005, 55(5): 420-424.
[44]	Kalapos-Kovács B, Juhász V, Temesszentandrási-Ambrus C, et al. Baicalin is a substrate of OATP2B1 and OATP1B3 [J]. Phytother Res, 2018, 32(8): 1647-1650.
[45]	杨艳秋, 刘贵军, 熊丽辉. 黄芩的主要成分对Caco-2细胞P-gp表达的影响 [J]. 中药材, 2016, 39(9): 2122-2125.
[46]	Akao T, Kawabata K, Yanagisawa E, et al. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form [J]. J Pharmacy Pharmacol, 2000, 52(12): 1563-1568.
[47]	张佳丽, 基于CYP3A和P-gp的黄芩苷药物相互作用研究 [D]. 郑州大学, 2019.
[48]	黄凯, 刘志浩, 贺晴. 黄芩苷对大鼠和人肝微粒体CYP450酶的抑制作用 [J]. 中国实验方剂学杂志, 2016, 22(3): 20-23.